Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Millan

Showing results (1-10 of 188) with videos related to

Pageof 19
Sort By:
Neuropharmacology|December 19, 2012
An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapyMark J Millan
Pharmacology & Therapeutics|March 9, 2006
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic applicationMark J Millan
Progress in Neurobiology|May 30, 2002
Descending control of painMark J Millan
Dialogues in Clinical Neuroscience|November 4, 2014
The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity?Mark J Millan
Therapeutic Advances in Psychopharmacology|July 7, 2022
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of actionMark J Millan
Progress in Neurobiology|March 22, 2017
Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: An integrative reviewMark J Millan
Progress in Neurobiology|August 21, 2003
The neurobiology and control of anxious statesMark J Millan
Pain|July 1, 1994
Serotonin and pain: evidence that activation of 5-HT1A receptors does not elicit antinociception against noxious thermal, mechanical and chemical stimuli in miceMark J Millan
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 27, 2008
Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsMark J Millan
Medecine Sciences : M/S|April 7, 2005
[Dopamine D3 receptors as a novel target for improving the treatment of schizophrenia]Mark J Millan
Pageof 19

Showing results (1-10 of 188) with videos related to

Sort By:
Pageof 19
Neuropharmacology|December 19, 2012
An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapyMark J Millan
Pharmacology & Therapeutics|March 9, 2006
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic applicationMark J Millan
Progress in Neurobiology|May 30, 2002
Descending control of painMark J Millan
Dialogues in Clinical Neuroscience|November 4, 2014
The epigenetic dimension of Alzheimer's disease: causal, consequence, or curiosity?Mark J Millan
Therapeutic Advances in Psychopharmacology|July 7, 2022
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of actionMark J Millan
Progress in Neurobiology|March 22, 2017
Linking deregulation of non-coding RNA to the core pathophysiology of Alzheimer's disease: An integrative reviewMark J Millan
Progress in Neurobiology|August 21, 2003
The neurobiology and control of anxious statesMark J Millan
Pain|July 1, 1994
Serotonin and pain: evidence that activation of 5-HT1A receptors does not elicit antinociception against noxious thermal, mechanical and chemical stimuli in miceMark J Millan
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 27, 2008
Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugsMark J Millan
Medecine Sciences : M/S|April 7, 2005
[Dopamine D3 receptors as a novel target for improving the treatment of schizophrenia]Mark J Millan
Pageof 19